共 44 条
- [21] A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease (vol 12, pg 1921, 2018)CLINICAL OPHTHALMOLOGY, 2019, 13 : 215 - 215Tauber, J.Schechter, B. A.Bacharach, J.
- [22] Phase 2, randomized, prospective, double-masked, vehicle-controlled study to assess the safety and efficacy of topical NEXAGON® in subjects with persistent corneal epithelial defects (PCED) resulting from severe ocular chemical and/or thermal injuriesINVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)Scranton, ShawnHou, JoshuaChoudhary, DharamveerGreen, ColinFeldman, MariaPanigrahi, Dipak
- [23] Blinded, Double-Dummy, Parallel-Group, Phase 2a Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Highly Selective 5-Hydroxytryptamine Type 4 Receptor Agonist in Critically Ill Patients With Enteral Feeding IntoleranceJOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 2021, 45 (01) : 115 - 124Chapman, Marianne J.Jones, Karen L.Almansa, CristinaBarnes, Chris N.Nguyen, DeannaDeane, Adam M.
- [24] A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin-0.1% dexamethasone combination compared to 1% azithromycin alone, 0.1% dexamethasone alone, and vehicle in the treatment of subjects with blepharitisCLINICAL OPHTHALMOLOGY, 2016, 10 : 1495 - 1503Hosseini, KamranLindstrom, Richard L.Foulks, GaryNichols, Kelly K.
- [25] ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye DiseaseCORNEA, 2022, 41 (10) : 1207 - 1216Wirta, DavidTorkildsen, Gail L.Boehmer, BlairHollander, David A.Bendert, EdwardZeng, LijuanAckermann, MichaelNau, Jeffrey
- [26] COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT)EXPERT OPINION ON DRUG SAFETY, 2024, 23 (06) : 743 - 754Kandarakis, StylianosPapadopoulos, Alexandros P.Roussopoulos, GeorgiosGeorgopoulos, EustathiosChung, YoungsikDoumazos, LeonidasBaek, AreumPaizi, Nefeli IoannaShin, HyunikPapadopoulos, Pantelis A.
- [27] Results of A Randomized, Double-Masked, Parallel-Arm Phase 2b Study Evaluating the Safety and Efficacy of OTX-TP (travoprost insert) Compared to Timolol Drops for the Treatment of Patients with Open-Angle Glaucoma or Ocular HypertensionINVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)Wilson, ChristineSall, Kenneth N.Bafna, ShamikGira, Joseph P.McLaurin, Eugene B.Protzko, EugeneSampson, ReginaldTekwani, NavinTepedino, MichaelVold, StevenWalters, Thomas R.Metzinger, Jamie LynneMulani, DeepaTalamo, Jonathan H.
- [28] Efficacy and Safety of SID142 in Patients With Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Clinical TrialCLINICAL THERAPEUTICS, 2022, 44 (04) : 508 - +Kook, HyungdonYu, Cheol WoongChoi, DonghoonAhn, Tae HoonChang, KiyukCho, Jin-ManKim, Soo-JoongPark, Chang GyuCho, Deok-KyuKim, Sang-HyunLee, Han CheolJin, Han-YoungChae, In-HoKwon, KihwanAhn, Sung GyunKim, Ju HanLee, Sang-RokKim, Jeong-SuKim, Seok YeonLim, Sang Wook
- [29] A Multicenter, Randomized, Placebo-Controlled, Parallel Group; Double-Blind, Phase II Trial To Evaluate the Efficacy and Safety and To Determine the Optimal Dose of LC15-0444 in Korean Subjects with Type 2 DiabetesDIABETES, 2010, 59 : A174 - A174Rhee, Eun-JungLee, Won-YoungYoon, Kun-HoYoo, Soon-JipLee, In-KyuBaek, Se-HyunKim, Yong KiLee, Moon-KyuPark, Kyung-SooPark, Joong-YeolCha, Bong-SooLee, Hyung-WooMin, Kyung-WanBae, Hak-YeonKim, Min-JeongKim, Jeong-AeKim, Dong-KyuKim, Sun-Woo
- [30] Safety and Preliminary Efficacy Results of a Novel Mesenchymal Stromal Cell Therapy in Diabetic Kidney Disease: The Multicenter, Randomized, Placebo-Controlled, Phase-1b/2a NEPHSTROM Clinical TrialJOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 29 - 29Griffin, Matthew D.Remuzzi, GiuseppeCockwell, PaulMaxwell, Alexander P.Perico, NorbertoRuggenenti, Piero L.Introna, MartinoFinnerty, Andrew A.Smythe, JonFibbe, Willem E.Elliman, Stephen J.O'Brien, Timothy